These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases. Jiang T; Chu Q; Wang H; Zhou F; Gao G; Chen X; Li X; Zhao C; Xu Q; Li W; Wu F; Xiong A; Zhao J; Xu Y; Su C; Ren S; Zhou C; Hirsch FR Int J Cancer; 2019 May; 144(10):2605-2612. PubMed ID: 30387880 [TBL] [Abstract][Full Text] [Related]
6. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature. Ashworth A; Rodrigues G; Boldt G; Palma D Lung Cancer; 2013 Nov; 82(2):197-203. PubMed ID: 24051084 [TBL] [Abstract][Full Text] [Related]
7. Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs. Xu Q; Zhou F; Liu H; Jiang T; Li X; Xu Y; Zhou C J Thorac Oncol; 2018 Sep; 13(9):1383-1392. PubMed ID: 29852232 [TBL] [Abstract][Full Text] [Related]
8. Outcome of radical local treatment of non-small cell lung cancer patients with synchronous oligometastases. Kwint M; Walraven I; Burgers S; Hartemink K; Klomp H; Knegjens J; Verheij M; Belderbos J Lung Cancer; 2017 Oct; 112():134-139. PubMed ID: 29191586 [TBL] [Abstract][Full Text] [Related]
9. Radical consolidative treatment provides a clinical benefit and long-term survival in patients with synchronous oligometastatic non-small cell lung cancer: A phase II study. Arrieta O; Barrón F; Maldonado F; Cabrera L; Corona-Cruz JF; Blake M; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; García O; Arén O; De la Garza J Lung Cancer; 2019 Apr; 130():67-75. PubMed ID: 30885354 [TBL] [Abstract][Full Text] [Related]
10. Might radiation therapy in addition to chemotherapy improve overall survival of patients with non-oligometastatic Stage IV non-small cell lung cancer?: Secondary analysis of two prospective studies. Su S; Hu Y; Ouyang W; Ma Z; Li Q; Li H; Wang Y; Wang X; Li T; Li J; Chen M; Lu Y; Bai Y; He Z; Lu B BMC Cancer; 2016 Nov; 16(1):908. PubMed ID: 27871270 [TBL] [Abstract][Full Text] [Related]
11. Lung Metastases Treated With Stereotactic Ablative Radiation Therapy in Oligometastatic Colorectal Cancer Patients: Outcomes and Prognostic Factors After Long-Term Follow-Up. Agolli L; Bracci S; Nicosia L; Valeriani M; De Sanctis V; Osti MF Clin Colorectal Cancer; 2017 Mar; 16(1):58-64. PubMed ID: 27522627 [TBL] [Abstract][Full Text] [Related]
12. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach. Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057 [TBL] [Abstract][Full Text] [Related]
13. Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer. Kissel M; Martel-Lafay I; Lequesne J; Faivre JC; Le Péchoux C; Stefan D; Barraux V; Loiseau C; Grellard JM; Danhier S; Lerouge D; Chouaid C; Gervais R; Thariat J BMC Cancer; 2019 Dec; 19(1):1237. PubMed ID: 31856742 [TBL] [Abstract][Full Text] [Related]
14. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Sørensen M; Pijls-Johannesma M; Felip E; Ann Oncol; 2010 May; 21 Suppl 5():v120-5. PubMed ID: 20555060 [No Abstract] [Full Text] [Related]
15. Radical treatment of oligometastatic non-small cell lung cancer: Ready for prime time? Brighenti M; Petrelli F; Barni S; Conti B; Sarti E; Ratti M; Panni S; Passalacqua R; Bersanelli M Eur J Cancer; 2017 Jul; 79():149-151. PubMed ID: 28494405 [TBL] [Abstract][Full Text] [Related]
16. A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC). Panje CM; Dedes KJ; Matter-Walstra K; Schwenkglenks M; Gautschi O; Siano M; Aebersold DM; Plasswilm L; Lupatsch JE; Radiother Oncol; 2018 Nov; 129(2):257-263. PubMed ID: 30104008 [TBL] [Abstract][Full Text] [Related]
17. A systematic overview of chemotherapy effects in non-small cell lung cancer. Sörenson S; Glimelius B; Nygren P; Acta Oncol; 2001; 40(2-3):327-39. PubMed ID: 11441939 [TBL] [Abstract][Full Text] [Related]
18. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Ashworth AB; Senan S; Palma DA; Riquet M; Ahn YC; Ricardi U; Congedo MT; Gomez DR; Wright GM; Melloni G; Milano MT; Sole CV; De Pas TM; Carter DL; Warner AJ; Rodrigues GB Clin Lung Cancer; 2014 Sep; 15(5):346-55. PubMed ID: 24894943 [TBL] [Abstract][Full Text] [Related]
19. Outcomes of a Highly Selective Surgical Approach to Oligometastatic Lung Cancer. Johnson KK; Rosen JE; Salazar MC; Boffa DJ Ann Thorac Surg; 2016 Oct; 102(4):1166-71. PubMed ID: 27344278 [TBL] [Abstract][Full Text] [Related]
20. Local treatment of oligometastatic recurrence in patients with resected non-small cell lung cancer. Yano T; Okamoto T; Haro A; Fukuyama S; Yoshida T; Kohno M; Maehara Y Lung Cancer; 2013 Dec; 82(3):431-5. PubMed ID: 24113550 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]